PMD News and Press, Psychemedics Corporation From 03/23/21

ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020. The Company's revenue ...

ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely p...

Psychemedics Corporation pioneered the first commercially-available drug test for hair in 1986 and states that it has the best hair follicle test on the market currently. If we run-rate 3Q revenues to $20M, I think it can achieve 15-20% operating margins, or $3-$4M in operating income...

ACTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek has joined the Company as Vice President, Controller. In this important role, Andrew will be responsible for directing and managing all of the Company’s financial...

ACTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel. In this important role, Sarah will be responsible for directing and managing all of the company’s legal...

ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020. The Company’s revenue for the quarter ended September 30, 2020 was $5.2 million versus $9.9 million for...

Praxis Precision Medicines has filed proposed terms for its U.S. IPO. The firm is developing treatments for various central nervous system and other disorders. PRAX has demonstrated positive early efficacy results, so for life science investors, the IPO is worth a close look. ...

ACTON, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020.  The Company’s revenue for the quarter ended June 30, 2020 was $3.3 million versus $9.3 million for the q...

ACTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD ), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced a Vaping Panel to detect the use of Marijuana, CBD and Nicotine. This test provides a way for schools and ...

ACTON, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD ), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the first FDA-cleared hair test for cotinine, the predominant metabolite for nicotine.  This test p...